Program
asciminib
Also written as “Asciminib”, “Asciminib single agent” and “ABL001”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase · Bronchiolitis Obliterans Syndrome · Renal Insufficiency, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 167 open or running | phase 4since May 4, 2021 | Feb 28, 2014 | Sep 3, 2027phase 2 · NCT04925479 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 28, 2014.
- Apr 27, 2016Phase 1 study in Hepatic ImpairmentNCT02857868 · 32 enrolled · United States
- Mar 9, 2017Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03106779 · 233 enrolled · United States, Argentina, Australia and more
- Jun 15, 2018Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03578367 · 104 enrolled · United States, Austria, Canada and more
- Jul 20, 2018Phase 1 study in Renal InsufficiencyNCT03605277 · 14 enrolled · Bulgaria, Germany
- Dec 7, 2020Phase 3 study in Leukemia, Myeloid, Chronic-PhaseNCT04666259 · 56 enrolled · United States
- Mar 10, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04795427 · 84 enrolled · China
- May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522 · 347 planned · United States, Argentina, Austria and more
- May 18, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479 · 46 enrolled · United States, China, France and more
- Jun 8, 20212 phase 3 studies in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04971226, NCT04948333
- May 17, 2022Phase 2 study in Leukemia, Myeloid, Chronic-PhaseNCT05384587 · 34 enrolled · United States
- Jul 11, 2022Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT05456191 · 568 enrolled · United States, Argentina, Bulgaria and more
- May 20, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeNCT06427811 · 85 enrolled · India
- Jul 17, 2024Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534 · 20 planned · France
- Jan 15, 2026Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074 · 50 planned · United States, Australia, Brazil and more
Ahead
- Sep 3, 2027Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479
- Feb 17, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534
- Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522
- Feb 23, 2033Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| nilotinibrule | Novartis | phase 4 | 57 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07354074Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Brazil and more | 2 | Recruiting | Feb 23, 2033 | 50 |
| NCT06514534Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France | 2 | Recruiting | Feb 17, 2029 | 20 |
| NCT06427811Bronchiolitis Obliterans Syndrome · India | 4 | Completed | Mar 18, 2026 | 85 |
| NCT05456191Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | May 15, 2025 | 568 |
| NCT05384587Leukemia, Myeloid, Chronic-Phase · United States | 2 | Active, not recruiting | Aug 13, 2025 | 34 |
| NCT04948333Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Austria, Brazil and more | 3 | Completed | Mar 12, 2024 | 199 |
| NCT04971226Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 28, 2023 | 405 |
| NCT04925479Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, China, France and more | 2 | Active, not recruiting | Sep 3, 2027 | 46 |
| NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 4 | Recruiting | Aug 30, 2030 | 347 |
| NCT04795427Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 2 | Completed | May 29, 2023 | 84 |
| NCT04666259Leukemia, Myeloid, Chronic-Phase · United States | 3 | Completed | Jun 20, 2023 | 56 |
| NCT03605277Renal Insufficiency · Bulgaria, Germany | 1 | Completed | Mar 18, 2019 | 14 |
| NCT03578367Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more | 2 | Completed | Nov 8, 2021 | 104 |
| NCT03106779Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more | 3 | Completed | May 25, 2020 | 233 |
| NCT02857868Hepatic Impairment · United States | 1 | Completed | Jul 20, 2017 | 32 |
| NCT02081378Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more | 1 | Completed | Jun 3, 2021 | 326 |
How it is read
Names in the registry
- “Asciminib”, 5 entries
- “Asciminib single agent”, 2 entries
- “ABL001”, 2 entries
- “asciminib”, 2 entries
- “Asciminib single agent pediatric formulation”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 11 studies
- Leukemia, Myeloid, Chronic-Phase, 2 studies
- Bronchiolitis Obliterans Syndrome, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.